Salo v. Tyler

2018 UT 7, 417 P.3d 581
CourtUtah Supreme Court
DecidedFebruary 22, 2018
DocketCase No. 20150520
StatusPublished
Cited by50 cases

This text of 2018 UT 7 (Salo v. Tyler) is published on Counsel Stack Legal Research, covering Utah Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Salo v. Tyler, 2018 UT 7, 417 P.3d 581 (Utah 2018).

Opinion

Associate Chief Justice Lee, opinion of the Court:

¶ 1 In 2011 David Salo was fired from Amgen, Inc., where he worked as a pharmaceutical representative. Salo later filed claims for defamation and interference with economic relations, asserting that three administrators at the University of Utah Hospital pharmacy-Linda Tyler, Kavish Choudhary, and John Vu-defamed him and caused him to lose his job. The district court dismissed these claims on summary judgment. We affirm.

¶ 2 In so doing we first clarify the operative summary judgment standard under rule 56 of the Utah Rules of Civil Procedure. Despite some confusing dicta to the contrary in Orvis v. Johnson , 2008 UT 2 , 177 P.3d 600 , *584 we hold that the Utah summary judgment standard is in line with the federal standard as set forth in Celotex Corp. v. Catrett , 477 U.S. 317 , 106 S.Ct. 2548 , 91 L.Ed.2d 265 (1986). In recent cases we have sought to clarify the standard as stated in Orvis and to reconcile it with the Celotex formulation. See, e.g. , Jones v. Trevor Mktg., Inc. v. Lowry , 2012 UT 39 , ¶ 30 n.9, 284 P.3d 630 . But confusion has continued-as evidenced by arguments in this case. And we now disavow any suggestion in Orvis that our Utah standard is distinct from the federal standard stated in Celotex . As in Celotex , we hold that the moving party always bears the burden of establishing the lack of a genuine issue of material fact, but the burden of production of evidence may fall on the nonmoving party (if that party will bear the burden of production at trial). And where the burden of production falls on the nonmoving party, we clarify that the moving party may carry its burden of persuasion without putting on any evidence of its own-by showing that the nonmoving party has no evidence to support an essential element of a claim.

¶ 3 We affirm summary judgment under this standard. We hold that the defendants were entitled to summary judgment under the Utah Governmental Immunity Act, Utah Code sections 63G-7-101 through 63G-7-904. That statute protects the governmental employees here from liability for acts within the scope of their employment unless their acts are shown to be willful. See id. § 63G-7-202(3). Here it is evident that the defendants acted within the scope of employment because they were clearly engaged in the general type of work they were employed to perform. And Salo produced no evidence that their actions were willful. We affirm on those grounds.

¶ 4 We also affirm the district court's decision to refuse to strike an affidavit submitted by Linda Tyler in support of the motion for summary judgment filed by Choudhary and Vu. Tyler was not listed as a potential witness at the time of the summary judgment motion, as required by rule 26(a) of the Utah Rules of Civil Procedure. But Tyler was identified in the defendants' rule 26(a) disclosures at every stage of the litigation until shortly before summary judgment, as was the subject of Tyler's testimony. For that reason we conclude that Salo was in no way prejudiced by the defendants' failure to identify Tyler as a witness. And we conclude that the district court acted within its discretion in denying the motion to strike.

I

¶ 5 In 2011 David Salo was working as a pharmaceutical representative for Amgen, Inc. His largest account was with the University of Utah Hospital system. He worked particularly closely with the Huntsman Cancer Hospital. Salo was also a member of the Medical Service Representatives Committee (MSR) at the hospital. In that volunteer capacity he helped coordinate the relationship between pharmaceutical companies such as Amgen, their drug representatives, and hospital administrators and staff.

¶ 6 On April 27, 2011, a nurse at the university hospital contacted Salo about a patient who suffered from bony-metastatic disease and giant cell tumor (GCT). The nurse reached out to Salo on behalf of Dr. Lance Gouw, a physician in the University of Utah hospital system. Dr. Gouw had developed a plan to treat the patient's GCT, a plan that included the use of denosumab, a drug manufactured by Amgen. Since the U.S. Food and Drug Administration (FDA) had not approved denosumab for treatment of GCT, Dr. Gouw's nurse inquired whether Salo had any information on treating GCT with the drug. Salo had never heard of GCT before and told the nurse he would get back to her. He also directed her to Amgen Medical Information for more information. Later Dr. Gouw's physician assistant Grace Noda followed up with Salo. Salo gave Noda the contact information of a doctor from MD Anderson Cancer Center who had experience using denosumab for GCT.

¶ 7 At the same meeting, Noda asked Salo about Amgen's patient assistance programs administered through the Amgen Foundation. The patient in question did not have commercial health insurance and thus was not eligible for the First Step Program. But Salo did provide information about Amgen's other program, the Safety Net Program, designed *585 for patients without insurance. Dr. Gouw later applied to the program on behalf of his patient.

¶ 8 Following his conversation with Noda, Salo called the hospital's pharmacy director to relate his conversations with Dr. Gouw's nurse and physician assistant, but the call dropped. Salo then called Vu and reported that he was aware that Dr. Gouw intended to use denosumab off-label but that he "had nothing to do with Dr. Gouw wanting to use [the drug] off-label." Salo also reported that he had given Noda the name of a physician who had experience using denosumab for GCT. Vu "took exception" to this news, remarking that "we're going to have to look into this."

¶ 9 Vu reported this conversation to Choudhary, writing about "perceived" off-label promotion of denosumab by Salo. Vu relayed that the "action of giving out the MD Anderson physician info would likely be considered off-label promotion." Choudhary also heard from the hospital's pharmacy director, who reported that certain hospital staff were under the impression that Salo had given Dr. Gouw Amgen's financial assistance debit cards for use for an off-label treatment. Choudhary forwarded this information to Tyler.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Krueger v. Seed Capital Investments
Court of Appeals of Utah, 2026
Al-Imari v. UDOT
2026 UT App 15 (Court of Appeals of Utah, 2026)
Fleming v. Dullanty
2025 UT App 128 (Court of Appeals of Utah, 2025)
Marriott v. Wilhelmsen
2025 UT 35 (Utah Supreme Court, 2025)
Feller Behavioral Health v. Military and Veteran
2025 UT 33 (Utah Supreme Court, 2025)
State v. Wilcox
2025 UT 31 (Utah Supreme Court, 2025)
GENESIS AGGREGATES B v. TOLL SOUTHWEST
2025 UT 28 (Utah Supreme Court, 2025)
Anderson v. Richards
Tenth Circuit, 2024
S6 v. Wing Enterprises
2024 UT App 105 (Court of Appeals of Utah, 2024)
Sabour v. Koller
2024 UT App 26 (Court of Appeals of Utah, 2024)
Beauty Lab and Laser v. Jelosek
2023 UT App 139 (Court of Appeals of Utah, 2023)
Geometwatch v. Utah State University
2023 UT App 124 (Court of Appeals of Utah, 2023)
Van Leeuwen v. Bana Resi-Non-Core
2023 UT App 91 (Court of Appeals of Utah, 2023)
In re Harding Trust
2023 UT App 81 (Court of Appeals of Utah, 2023)
Mariani v. Driver License Division
2023 UT App 79 (Court of Appeals of Utah, 2023)
Brown v. City of Fruit Heights
2023 UT App 39 (Court of Appeals of Utah, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
2018 UT 7, 417 P.3d 581, Counsel Stack Legal Research, https://law.counselstack.com/opinion/salo-v-tyler-utah-2018.